A Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers

Status:
Completed

Trial end date:
2012-03-01

Target enrollment:

Participant gender:

This study is an open-label Phase 1 trial of MM-111.

Phase 1

Merrimack Pharmaceuticals